Oral PCSK9 Inhibitor Tied to LDL-C Drop
-
by Kerri Miller
November 24, 2025
-
3 min
Enlicitide, an oral macrocyclic peptide and PCSK9 inhibitor, was evaluated in a phase 3 trial involving 303 adults with heterozygous familial hypercholesterolemia (HeFH). This study revealed a significant 58.2% reduction in LDL-C levels after 24 weeks of treatment compared to placebo. The trial demonstrated that enlicitide is effective in lowering cholesterol levels while maintaining a safety profile similar to placebo, with only mild adverse effects observed. Participants were already on high-intensity statins, and the trial is ongoing to determine long-term cardiovascular outcomes.
1. Enlicitide is a PCSK9 inhibitor. 2. Achieved a 58.2% reduction in LDL-C compared to placebo. 3. Trial involved 303 adults with HeFH across 17 countries. 4. Participants were on moderate to high-intensity statins. 5. LDL-C reductions sustained throughout the trial duration. 6. Adverse event rates were similar between groups. 7. Ongoing separate outcomes trial will assess cardiovascular effects. 8. Study funded by Merck Sharp & Dohme LLC.
Listen Tab content
